fig2

Approaches to identifying drug resistance mechanisms to clinically relevant treatments in childhood rhabdomyosarcoma

Figure 2. (A) Initial volume responses of 34 RMS models to cycle 1 of vincristine + actinomycin D + cyclophosphamide (VAC) using the SMT experimental design (ongoing expt.). (B) Kaplan-Meier plot for EFS of the same models. RMS: Rhabdomyosarcoma; VAC: vincristine/actinomycin-D/cyclophosphamide; EFS: event-free survival; SMT: single mouse testing.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/